Company news

Q32 Bio Inc. news in 2026

Q32 Bio Inc.'s news releases, calls and decks from 2026, newest first.

View company

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 4, 2026

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

September 30, 2026

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

September 21, 2026

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

September 14, 2026

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 5, 2026

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

July 14, 2026

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

July 13, 2026

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

July 13, 2026

Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026

July 10, 2026

Q32 Bio Announces $55 Million Private Placement Financing

May 27, 2026

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 7, 2026

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

March 9, 2026

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026

Q32 Bio Announces $10.5 Million Registered Direct Offering

February 17, 2026

Decks in 2026